These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 8024262)

  • 21. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
    Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autonomic dysfunction in patients with progressive supranuclear palsy.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Reichmann H; Berg D; Ziemssen T
    Mov Disord; 2008 Oct; 23(14):2083-9. PubMed ID: 18792126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repetitive transcranial magnetic stimulation in patients with progressive supranuclear palsy: a pilot study.
    Santens P; Sieben A; De Letter M
    Acta Neurol Belg; 2009 Sep; 109(3):200-4. PubMed ID: 19902813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T
    Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical rating scale for progressive supranuclear palsy.
    Golbe LI; Ohman-Strickland PA
    Brain; 2007 Jun; 130(Pt 6):1552-65. PubMed ID: 17405767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A 70-year-old man with a progressive gait disturbance and gaze palsy].
    Nakamura T; Yoritaka A; Sumino S; Suzuki H; Mori H; Suda K; Takubo H; Mizuno Y
    No To Shinkei; 1997 Jan; 49(1):93-100. PubMed ID: 9027910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers.
    Dukoff R; Wilkinson CW; Lasser R; Friz J; Conway A; Bahro M; Peskind ER; Sunderland T
    Biol Psychiatry; 1999 Jul; 46(2):189-95. PubMed ID: 10418693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progressive supranuclear palsy].
    Imai H
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1452-4. PubMed ID: 8752427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gaze control and foot kinematics during stair climbing: characteristics leading to fall risk in progressive supranuclear palsy.
    Di Fabio RP; Zampieri C; Tuite P
    Phys Ther; 2008 Feb; 88(2):240-50. PubMed ID: 18073265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive supranuclear palsy.
    Esper CD; Weiner WJ; Factor SA
    Rev Neurol Dis; 2007; 4(4):209-16. PubMed ID: 18195676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinergic modulation of preattentive auditory processing in aging.
    Pekkonen E; Jääskeläinen IP; Kaakkola S; Ahveninen J
    Neuroimage; 2005 Aug; 27(2):387-92. PubMed ID: 15921933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frontal lobe function in progressive supranuclear palsy.
    Grafman J; Litvan I; Gomez C; Chase TN
    Arch Neurol; 1990 May; 47(5):553-8. PubMed ID: 2334303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease.
    Cordato NJ; Halliday GM; Caine D; Morris JG
    Mov Disord; 2006 May; 21(5):632-8. PubMed ID: 16353177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine.
    Matsuoka N; Aigner TG
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1201-9. PubMed ID: 9067304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic approaches to the treatment of progressive supranuclear palsy.
    Litvan I
    J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A clinical and epidemiological description of a series of patients diagnosed as suffering from progressive supranuclear palsy].
    Alvarez-González E; Maragoto-Rizo C; Arteche-Prior M; Pérez-Parra S; Carballo M; Alvarez-González L
    Rev Neurol; 2004 Dec 1-15; 39(11):1006-10. PubMed ID: 15597260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholinergic modulation of spatial working memory of mice in radial maze performance: retention curve analysis.
    Inagawa K
    Yakubutsu Seishin Kodo; 1993 Aug; 13(4):233-8. PubMed ID: 8237140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat.
    Waters KA; Burnham KE; O'connor D; Dawson GR; Dias R
    J Psychopharmacol; 2005 Mar; 19(2):149-58. PubMed ID: 15728436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of the vesicourethral function between progressive supranuclear palsy and Parkinson's disease].
    Wakatsuki A; Tsujihata M; Miyake O; Ito H; Itatani H; Udaka F
    Hinyokika Kiyo; 1993 Jun; 39(6):523-8. PubMed ID: 8337978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.